Corporate News Releases

ZyVersa Therapeutics' Viewpoint on "Why Kidney Indications Are Coming into Sharp Focus" Reported in BIOCENTURY Innovations' Article
Interview with ZyVersa Therapeutics' CEO, Stephen C. Glover, Published in CEOCFO Magazine
ZyVersa Therapeutics Unveils a White Paper Fostering Education About Inflammasomes and Their Potential as a Promising Therapeutic and Diagnostic Target for Inflammatory Diseases
ZyVersa Therapeutics' Perspectives on Inflammasomes Reported in BIOCENTURY Innovations Article
ZyVersa Therapeutics Advances Development of Lead Inflammasome Inhibitor Candidate, IC 100
ZyVersa Therapeutics to Attend the World's Largest Biotechnology Partnering Event, BIO International (Philadelphia, June 3 - 6, 2019)
ZyVersa Therapeutics Announces Appointment of International Investor, Andrew (DW) Kim, to its Board of Directors
Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board
ZyVersa Therapeutics Enhances Scientific Advisory Board with Three Esteemed Nephrologists
Jules A. Müsing, Former Senior Executive at Johnson & Johnson, Has Been Appointed Chairman of ZyVersa Therapeutics' Board of Directors